Qiagen.
company
- Reports this week
- 0
- Active events
- 0
- Connections
- 91
What's happening
Earlier this month
-
Berenberg Bank has set a target price for Qiagen shares.Some support5 reports
-
Private equity is seeking to acquire Qiagen, while Abu Dhabi Investment Authority (ADIA) holds subsidiary interest in EQT.Some support2 reports1 development inside
-
EQT agreed to acquire Qiagen in an all-cash deal, and Baird raised its price target for Qiagen shares.Some support1 report
-
Qiagen N.V. is a Netherlands-based holding company.Well supported13 reports1 development inside
One to three months ago
-
Qiagen and Thermo Fisher Scientific Inc. were compared based on financial metrics on September 15, 2026.Some support2 reports
-
Thierry Bernard became the CEO of Qiagen on August 8, 2026.Some support2 reports
-
Qiagen operates within the District of Delaware.Some support1 report
-
Qiagen received FDA clearance for its diagnostic product, QIAstat-Dx Rise, expanding access in the U.S. on September 3, 2025.Well supported3 reports
Gone quiet
No new reports in 90+ days-
Qiagen reported sales declines in EMEA and overall sales in the low teens year over year in August 2026.Some support1 report
-
Illumina, AbbVie, Abbott Laboratories, Qiagen, and Eli Lilly are major players in the US personalized medicine market and are investing in related R&D.Some support1 report1 development inside
-
The IVD market in India is driven by NCDs, with key companies like Roche, Sysmex, Danaher, Qiagen, and Quidel leading innovation-driven growth.Some support1 report
-
A market report published from Dublin details advanced molecular diagnostics and key players in the hemato-oncology testing market.Some support1 report
-
Golden Cross (Q10290401) and Qiagen (Q315287) experienced a Golden Cross on June 23, 2025, when the 50-day moving average crossed above the 200-day moving average.Speculative1 report
-
Qiagen has shown better earnings estimate revision trends.Speculative1 report
-
Collaboration between Qiagen and Incyte to develop a novel diagnostic panel, leveraging FDA approvals for market access in the US.Speculative2 reports
-
Qiagen, Gencurix, and Genoox collaborated on July 3, 2025, to provide oncology assays and improve genetic data analysis capacity.Speculative1 report
-
Exact Sciences and Qiagen are considered value stocks in the sector as of July 10, 2025.Some support1 report
-
Illumina and Qiagen are noted as top players in the tumor profiling market experiencing growth in Europe.Some support1 report
-
Qiagen and CervoMed Inc. are both companies operating within the medical/biomedical sector.Some support1 report
-
GE HealthCare, Exagen Inc., Biogen, and Qiagen were identified as key market players in the Personalized Medicine Market.Some support1 report
-
Qiagen and Incyte formed a partnership to develop a companion diagnostic for mutant calreticulin.Some support1 report
-
Qiagen, a Netherlands-based company, announced a share offering with restrictions on persons in South Africa.Some support1 report
-
Qiagen is facing an investigation into investor claims, handled by the law firm Pomerantz LLP.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Qiagen this week
News at the entities that move Qiagen most-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves Qiagen
-
Berenberg Bank TransactionalBT Group stock is traded on the London Stock Exchange, with Berenberg Bank reiterating a buy rating and Deutsche Bank reiterating a sell rating.Moves Qiagen
-
EQT TransactionalEQT acquired majority share in Acronis, while Drax plans a datacenter for AI and RAM prices hit a wall for AI PCs.Moves Qiagen
-
Frankfurt StructuralBirmingham is hosting a Christmas Market named after Frankfurt.Moves Qiagen
-
Securities and Exchange Commission StructuralStar Holdings sold a land parcel in Coney Island and filed its quarterly report with the SEC.Moves Qiagen
-
Morgan Stanley OperationalSurrozen utilized conference platforms hosted by Morgan Stanley in South San Francisco on September 1, 2026.Moves Qiagen
Connections
The 24 strongest of 91, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
EQT Transactional
EQT agreed to acquire Qiagen in an all-cash deal.
-
Incyte Operational
Qiagen and Incyte maintain a strategic partnership focused on developing and supplying companion diagnostics for Incyte's targeted therapies.
-
private equity Transactional
Private equity has made a takeover offer for Qiagen.
-
Frankfurt Structural
Qiagen is formally listed and operates on the Frankfurt Stock Exchange.
-
Securities and Exchange Commission Structural
Qiagen is subject to formal regulatory reporting requirements mandated by the SEC.
-
Thierry Bernard Structural
Thierry Bernard serves as the CEO of Qiagen.
-
FDA Structural
FDA provides necessary regulatory clearance and market listing for Qiagen's products to operate in the U.S. market.
-
JPMorgan Chase Structural
JPMorgan Chase holds a disclosed voting stake in Qiagen.
Show all 24 connections
-
Bank of America Structural
Bank of America holds a significant financial stake in Qiagen.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides financial ratings and price targets for Qiagen.
-
Morgan Stanley Operational
Morgan Stanley provides and updates analyst ratings for Qiagen.
-
China Shared context
Qiagen operates within the market context of China, where geopolitical factors like import tariffs impact its business profitability and sales performance.
-
Berenberg Bank Transactional
Berenberg Bank provides financial analysis, including target prices and ratings, for Qiagen shares.
-
Banque cantonale vaudoise Transactional
Banque cantonale vaudoise increased its stake in Qiagen's stock.
-
MarketBeat Mentioned together
MarketBeat provides consensus rating data for Qiagen.
-
DZ Bank Operational
DZ Bank influences Qiagen's market valuation by issuing stock rating downgrades.
-
Thermo Fisher Scientific Inc. Mentioned together
The companies are frequently co-mentioned in financial reports and comparisons.
-
TD Cowen Mentioned together
TD Cowen issues ratings on Qiagen shares.
-
Baird Mentioned together
Baird raised its price target for Qiagen shares, indicating analyst coverage and opinion.
-
Europe Shared context
Qiagen operates within the European market context, which is subject to regional sales performance fluctuations.
-
Delaware Shared context
Qiagen operates within the District of Delaware.
-
AllianceBernstein Transactional
AllianceBernstein is listed as an interested party in a potential acquisition involving Qiagen.
-
Netherlands Shared context
Qiagen is headquartered and operates within the Netherlands.
-
New York Shared context
Qiagen's financial reporting is contextualized by the New York time zone.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventAugust 2026
4 eventsShow 1 earlier month
June 2026
16 events- Qiagen N.V. is a Netherlands-based holding company.
- Qiagen received FDA clearance for its diagnostic product, QIAstat-Dx Rise, expanding access in the U.S. on September 3, 2025.
- Illumina, AbbVie, Abbott Laboratories, Qiagen, and Eli Lilly are major players in the US personalized medicine market and are investing in related R&D.
- The IVD market in India is driven by NCDs, with key companies like Roche, Sysmex, Danaher, Qiagen, and Quidel leading innovation-driven growth.
- A market report published from Dublin details advanced molecular diagnostics and key players in the hemato-oncology testing market.
- Golden Cross (Q10290401) and Qiagen (Q315287) experienced a Golden Cross on June 23, 2025, when the 50-day moving average crossed above the 200-day moving average.
- Qiagen has shown better earnings estimate revision trends.
- Collaboration between Qiagen and Incyte to develop a novel diagnostic panel, leveraging FDA approvals for market access in the US.
- Qiagen, Gencurix, and Genoox collaborated on July 3, 2025, to provide oncology assays and improve genetic data analysis capacity.
- Exact Sciences and Qiagen are considered value stocks in the sector as of July 10, 2025.
- Illumina and Qiagen are noted as top players in the tumor profiling market experiencing growth in Europe.
- Qiagen and CervoMed Inc. are both companies operating within the medical/biomedical sector.
- GE HealthCare, Exagen Inc., Biogen, and Qiagen were identified as key market players in the Personalized Medicine Market.
- Qiagen and Incyte formed a partnership to develop a companion diagnostic for mutant calreticulin.
- Qiagen, a Netherlands-based company, announced a share offering with restrictions on persons in South Africa.
- Qiagen is facing an investigation into investor claims, handled by the law firm Pomerantz LLP.